

United States Patent and Trademark Offici

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER POR PATENTS Address, Viginia 22313-1450 www.nisto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/701,572	01/29/2001	Eva Kondorosi	200204US0PCT	5065
22850	7590 09/10/2003			
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER	
			COLLINS, CYNTHIA E	
			ART UNIT	PAPER NUMBER
			1638	
			DATE MAILED: 09/10/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)
09/701,572	KONDOROSI ET AL.
Examiner	Art Unit
Cynthia Collins	1638

	Cynthia Collins	1030					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress				
THE REPLY FILED 11 August 2003 FAILS TO PLACE? Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this application of the control	ation. A proper reply h places the applica	to a tion in				
PERIOD FOR RE	PLY [check either a) or b)]						
 a) The period for reply expires 3 months from the mailing date 							
 The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). 	ater than SIX MONTHS from the mailin	g date of the final rejection	on.				
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filled is the date for purposes of determining the period fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (6) above, if checked. Any reply received by the Offitied, may reduce any earned patent term adjustment. See 37 C	If extension and the corresponding amo the shortened statutory period for reply be later than three months after the mai	unt of the fee. The appr originally set in the final	opriate extension Office action; or				
A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF).							
2. The proposed amendment(s) will not be entered be	ecause:						
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) They raise the issue of new matter (see Note below);							
(c) they are not deemed to place the application in issues for appeal; and/or	better form for appeal by mate	rially reducing or sin	nplifying the				
(d) M they present additional claims without cancell	ng a corresponding number of fi	nally rejected claims	6.				
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following reject	ion(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed a	amendment				
5.⊠ The a) affidavit, b) exhibit, or c) request for application in condition for allowance because: See		dered but does NOT	place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were	newly				
For purposes of Appeal, the proposed amendment explanation of how the new or amended claims wo			nd an				
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: 12-29.							
Claim(s) withdrawn from consideration:							
8. The proposed drawing correction filed on is	a) approved or b) disapp	oved by the Examir	er.				
9. Note the attached Information Disclosure Statemen	t(s)(PTO-1449) Paper No(s)	_^ T					
10. Other:		PluongK	milles				
		PHUONG T. BU					

Application/Control Number: 09/701,572

Art Unit: 1638

Continuation of 2. NOTE: newly added claims 30-31 are directed to "a nucleic acid", which raises new issues that would require further consideration and/or search under 35 USC §101; newly added claims 40-41 are directed to polynucleotides that encode a protein comprising amino acid residues 51-55 and 57 of SEQ ID NO:2, and a protein comprising amino acid residues 81, 84, 85, 90 and 91 of SEQ ID NO:2, which raises new issues that would require further consideration and/or search under 35 USC §112, 35 USC §102 and 35 USC §103; the amendment of claims 12 and 15 to recite "inhibits mitosis and induces endoreplication" raises new issues that would require further consideration and/or search under 35 USC §112, second paragraph, as it is unclear where and under what conditions mitosis would be inhibited and endoreplication would be induced.

Continuation of 5. does NOT place the application in condition for allowance because: the specification does not describe or enable fragments of SEQ ID NO:1 which comprise WD-40 motifs and which inhibit mitosis and induce endoreplication; the acronym "CCS52Ms" is indefinite; the addition of the limitation "wherein similarity is determined using the BLAST program" to claims 16 and 18 does not overcome the rejection under 35 U.S.C. 112, second paragraph, for indefiniteness in the recitation of "% similar" - it is suggested that the claims be amended to recite % "sequence identity" in order to overcome the rejection under 35 U.S.C. 112, second paragraph.